147 related articles for article (PubMed ID: 1099859)
1. Serum lipids during oestradiol-valerate/norgestrel treatment of menopausal women. Double-blind study of a sequential preparation.
Christensen NC; Davidsen PC; Secher NJ; Pedersen GT
Acta Obstet Gynecol Scand; 1975; 54(3):213-6. PubMed ID: 1099859
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum lipids during treatment with norgestrel, oestradiol-valerate and cycloprogynon.
Nielsen FH; Honoré E; Kristoffersen K; Secher NJ; Pedersen GT
Acta Obstet Gynecol Scand; 1977; 56(4):367-70. PubMed ID: 602705
[TBL] [Abstract][Full Text] [Related]
3. The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women.
Paterson ME; Sturdee DW; Moore B; Whitehead TP
Br J Obstet Gynaecol; 1980 Jul; 87(7):552-60. PubMed ID: 6252948
[TBL] [Abstract][Full Text] [Related]
4. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
7. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
8. Long-term post-menopausal hormone therapy and serum HDL-C, total cholesterol and triglycerides.
Vilska S; Punnonen R; Rauramo L
Maturitas; 1983 Aug; 5(2):97-104. PubMed ID: 6415365
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
Nash AL; Cornish EJ; Hain R
Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
[TBL] [Abstract][Full Text] [Related]
12. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
13. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
14. Effects of oestradiol valerate plus two different progestogens on serum lipids during post-menopausal replacement therapy.
Makkonen M; Saarikoski S; Penttilä I
Maturitas; 1991 Dec; 14(1):43-8. PubMed ID: 1791771
[TBL] [Abstract][Full Text] [Related]
15. Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation.
Bostofte E; Hemmingsen L; Møller KJ; Serup J; Weber T
Acta Endocrinol (Copenh); 1978 Apr; 87(4):855-64. PubMed ID: 347855
[TBL] [Abstract][Full Text] [Related]
16. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
17. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses.
Krauss RM; Roy S; Mishell DR; Casagrande J; Pike MC
Am J Obstet Gynecol; 1983 Feb; 145(4):446-52. PubMed ID: 6401927
[TBL] [Abstract][Full Text] [Related]
18. Lipid metabolic studies in oophorectomized women: effects induced by two different estrogens on serum lipids and lipoproteins.
Silfverstolpe G; Gustafson A; Samsioe G; Svanborg A
Gynecol Obstet Invest; 1980; 11(3):161-9. PubMed ID: 7439809
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
[TBL] [Abstract][Full Text] [Related]
20. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A
Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
